Contact CFFC

Sep

Clinical Trial Alerts – September 2021

Cystic Fibrosis Foundation has issued the following clinical trial alerts in September.

September 7, 2021

Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a)

Status: Enrolling

Description: This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40% or greater

Number of Visits: 9

Length of Participation: 192 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05010577

Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a)

Status: Enrolling

Description: This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40% or greater

Number of Visits: 11

Length of Participation: 189 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05010577


Comments are closed.